Janumet is fixed-dose combination drug that helps to regulate blood glucose levels. It is made up of metformin HCL (a biguanide) and sitagliptin (a dipeptidyl peptidase-4 or DPP-4 enzyme inhibitor). The two ingredients act synergistically to improve glucose tolerance in diabetic individuals. It is particularly useful for type II diabetic patients who fail to achieve adequate glycemic control with diet/exercise alone. Apart from the 50mg/ 850mg preparation, this medication is also available in the dosage strengths of 50mg/ 500mg and 50mg/ 1000mg. Janumet is a prescription-only drug developed by Merck
Janumet is specially designed to improve blood sugar control in diabetic patients over 18 years of age. The drug is usually used as part of a larger management plan, which usually includes exercise and/or diet. It is effective in the treatment of type II diabetes, but not type I diabetes mellitus or diabetic ketoacidosis. It is unknown if Janumet has any effects on the unborn baby. As a precaution, pregnant patients should consult the doctor before using Janumet (the same goes for those who plan to get pregnant). Using Janumet in individuals with a history of pancreatitis may result in disease recurrence.
The dual action drug significantly improves blood glucose control in diabetic patients. Being FDA-approved, Janumet is clinically proven effective and safe.